EP640 - ECE_3474 - Correlation of weight loss and SF-36 physical function score in weight management with semaglutide injection: post-hoc analysis of phase 3 Study
Year: 2026
Type: conference-abstract
Abstract: Objectives To evaluate the correlation between weight loss and quality of life as assessed by SF-36 (36 item shoer form survey) questionnaire in patients treated with Semaglutide injection for weight management Materials and Methods This phase III, multicentre, randomized, open-label, active-controlled clinical study (CTRI/2025/04/085487) was conducted across 22 study sites in India after receiving regulatory and ethics committee approvals. Total 267 adult patients with BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 with the presence of at least one co-morbidity of hypertension, dyslipidaemia and/or type 2 diabetes mellitus were included. Patients were randomized to either test arm to receive synthetic semaglutide injection or reference arm to receive Wegovy® every week subcutaneously for 24 weeks. The primary endpoint was change in body-weight from baseline to week 24. Secondary endpoints included change in BMI, waist circumference, SF-36, and glycaemic measures in diabetic and non-diabetic patients. Safety assessments included incidence of TEAEs and anti-drug/neutralizing antibody. This post-hoc analysis was conducted to evaluate the correlation between weight loss and improvement in quality of life as assessed by SF-36 physical function score. Results The Pearson’s correlation coefficient between change in weight loss and SF-36 physical functioning score was −0.155 with P value = .0467 in test arm. The Pearson’s correlation coefficient between change in weight loss and SF-36 physical functioning score was -0.046 with P value = .6831 in reference arm. There is negative correlation between weight loss and change in SF-36 physical functioning score in both test and reference arm indicating greater reduction in weight loss is associated with more increase in SF-36 score signifying improvement is SF-36 total score. The correlation between weight loss and improvement in SF-36 physical functioning score was statistically significant in test arm. The statistical significance observed in the Pearson correlation analysis in test arm supports the robustness of this association. Conclusions This post-hoc analysis demonstrated that there is improvement in quality of life as measured by SF-36 physical function score with reduction in weight, in patients treated with semaglutide injection for weight management.
Authors: Unnikrishnan Gopalkrishnan, Ameya Joshi, Harish Kumar, Richa Giri, Sanjiv Maheshswari, Valluri Prasad, Jitendra Shukla, M C Rekha, Nutankumar Agrawal, Yogesh Rasal, Banshidhar Sahoo, Shweta Bhandari, Ambana Gowda, Phadke Keshav, Pravin Supe, Niranjan Pathak, C Ambrish, Ashutosh Sonawane, Yash Bahulikar, Amit Bhaskar, R Arunkumar, Priyanka Yadav, Supriya Sonowal, Dipak Patil, Sucheta Pandit, Pravin Ghadge, Suyog Mehta
Institutions: Chellaram Hospital, Bhaktivedanta Hospital & Research Institute, Amrita Institute of Medical Sciences and Research Centre, Ganesh Shankar Vidyarthi Memorial Medical College, Jawaharlal Nehru Medical College, King George Hospital, Mandya Institute of Medical Sciences, Maharani Laxmi Bai Medical College, Sahyadri Hospital, Joshi Hospital, Chettinad Health City
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,292
OpenAlex ID: W7213244754